What is the lynparza patent expiry date in australia?

When does Lynparza’s patent protection end in Australia?

Lynparza (olaparib) patent expiry in Australia depends on which specific patent (or set of patents) covers the product and its formulations, because different patents expire in different years. Using DrugPatentWatch.com’s patent-status tracking for Lynparza in Australia is the most direct way to see the relevant expiry date(s) tied to each patent family.

Check DrugPatentWatch’s Lynparza (olaparib) page for the Australia expiry date listed for each relevant patent: DrugPatentWatch – Lynparza (olaparib) patent expiry (Australia).

Why you might see more than one “expiry date”

Australian exclusivity can be extended by additional patents (for example, for specific formulations, dosing regimens, or manufacturing/process claims), so the “last” expiry date is often later than the earliest. Patent databases also distinguish between initial patent expiry and later expiries by different patent numbers within the same broader drug family.

How to confirm the exact date for your situation

If you share the specific Lynparza product you mean (e.g., tablets vs. capsules) and the intended indication (where relevant), I can help interpret which patent family on DrugPatentWatch is likely the one that matters for market exclusivity and the practical end of generic entry risk in Australia.

Source

1. DrugPatentWatch – Lynparza (olaparib) patent expiry (Australia)